ClinicaliQ Trial Snapshot
- Visugromab in Cachexia International Trial — Recruiting • Phase II • Oncology • NCT07112196.
- What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for safety and efficacy in treating cancer-associated cachexia (unintended weight loss) across patients with solid tumours including lung and bowel cancer.
- Patient eligibility overview: The trial enrolls patients with advanced solid malignancies (particularly lung and colorectal cancer) who are experiencing clinically significant cachexia, meeting specific criteria for weight loss and performance status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit…
Eligibility Snapshot
- : * Weight loss * Advanced cancer
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.